Skip to content

Self-sampling for Non-participants in an Organised Cervical Cancer Screening Programme

A Three-armed Randomised Controlled Trial of Non-participants in an Organised Cervical Cancer Screening Programme

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02680262
Acronym
CHOiCE
Enrollment
9327
Registered
2016-02-11
Start date
2016-03-31
Completion date
2018-02-01
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

HPV self-sampling, cervical cancer screening

Brief summary

The trial will evaluate the effect on participation in organised screening programme of a human papilloma virus (HPV) self-sampling kit directly mailed home or mailed on demand compared with the standard second reminder for regular screening.

Detailed description

The CHOice trial is a parallel randomised controlled, open label trial. Participants will be equally randomised into three arms: 1) Directly mailed a second reminder including a HPV self-sampling kit; 2) Mailed a second reminder offering a HPV self-sampling kit, to be ordered by e-mail, by text message, by phone, or by website; and 3) Mailed a second reminder for a conventional practitioner-collected sample (control group).

Interventions

BEHAVIORALHPV self-sampling kit mailed directly

Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.

BEHAVIORALHPV self-sampling kit on demand

Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit. The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure).

BEHAVIORALSecond reminder

The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Women resident in the Central Denmark Region who have not participate in cervical cancer screening after an invitation and one reminder

Exclusion criteria

* Women younger than 30 years are not included due to the lower specificity of HPV DNA tests in younger women

Design outcomes

Primary

MeasureTime frameDescription
Women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out.90 daysPrimary outcome will be the proportion of women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out.

Secondary

MeasureTime frameDescription
Women with a positive HPV self-collected sample who attend follow-up testing at 30, 60 or 90 days after mail out.30,60 or 90 daysSecondary outcome will be the proportion of women with a positive HPV self-collected sample who attend follow-up testing at 30, 60 or 90 days after mail out of results

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026